Business Description
Checkpoint Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1628282063
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -0.86 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -51.64 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -70.3 | |||||
3-Year EBITDA Growth Rate | 12.5 | |||||
3-Year EPS without NRI Growth Rate | 8.1 | |||||
3-Year FCF Growth Rate | 5 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 60.78 | |||||
9-Day RSI | 63.3 | |||||
14-Day RSI | 60.32 | |||||
6-1 Month Momentum % | -29.87 | |||||
12-1 Month Momentum % | -48.48 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.54 | |||||
Quick Ratio | 0.54 | |||||
Cash Ratio | 0.51 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -58.7 | |||||
Shareholder Yield % | -59.17 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -66195.59 | |||||
Net Margin % | -76938.24 | |||||
FCF Margin % | -57964.06 | |||||
ROA % | -773.82 | |||||
ROIC % | -1527.83 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 460 | |||||
EV-to-EBIT | -1.26 | |||||
EV-to-Forward-EBIT | -1.24 | |||||
EV-to-EBITDA | -1.26 | |||||
EV-to-Forward-EBITDA | -1.24 | |||||
EV-to-Revenue | 831.82 | |||||
EV-to-Forward-Revenue | 543.53 | |||||
EV-to-FCF | -1.41 | |||||
Earnings Yield (Greenblatt) % | -79.37 | |||||
FCF Yield % | -59.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Checkpoint Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.064 | ||
EPS (TTM) (€) | -2.554 | ||
Beta | 1.27 | ||
Volatility % | 75.58 | ||
14-Day RSI | 60.32 | ||
14-Day ATR (€) | 0.063804 | ||
20-Day SMA (€) | 1.5045 | ||
12-1 Month Momentum % | -48.48 | ||
52-Week Range (€) | 1.286 - 3.128 | ||
Shares Outstanding (Mil) | 36.85 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Checkpoint Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Checkpoint Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Checkpoint Therapeutics Inc Frequently Asked Questions
What is Checkpoint Therapeutics Inc(STU:CZTA)'s stock price today?
When is next earnings date of Checkpoint Therapeutics Inc(STU:CZTA)?
Does Checkpoint Therapeutics Inc(STU:CZTA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |